Table 1.
Demographic and clinical findings of critically ill patients with COVID-19.
| All patients (n = 86) | Patients without AIS (n = 80) | Patients with AIS (n = 6) | |
|---|---|---|---|
| Age, years, mean ±SD | 66.6 ± 11.1 | 66.5 ± 11.5 | 68.2 ± 2.1 |
| Sex | |||
| Male, n (%) | 54 (62.8) | 49 (61.3) | 5 (83.3) |
| Presenting symptoms | |||
| Fever, n (%) | 75 (87.2) | 69 (86.3) | 6 (100) |
| Cough, n (%) | 65 (75.6) | 61 (76.3) | 4 (66.7) |
| Myalgia, n (%) | 15 (17.4) | 12 (15.0) | 3 (50.0) |
| Fatigue, n (%)* | 46 (53.5) | 40 (50.0) | 6 (100) |
| Headache, n (%) | 8 (9.3) | 7 (8.8) | 1 (16.7) |
| Dizziness, n (%) | 6 (7.0) | 5 (6.3) | 1 (16.7) |
| PMH | |||
| Hypertension, n (%) | 44 (51.1) | 41 (51.3) | 3 (50.0) |
| Diabetes, n (%) | 19 (22.1) | 17 (21.3) | 2 (33.3) |
| CAD, n (%) | 16 (18.6) | 14 (17.5) | 2 (33.3) |
| Ischemic stroke, n (%) | 7 (8.1) | 5 (6.3) | 2 (33.3) |
| Intracranial hemorrhage, n (%) | 4 (4.7) | 4 (5.0) | 0 (0) |
| Smoking, n (%) | 12 (14.0) | 11 (13.8) | 1 (16.7) |
| Complications | |||
| Arrhythmia, n (%) | 29 (33.7) | 28 (35.0) | 1 (16.7) |
| AF, n (%) | 16 (18.6) | 15 (18.8) | 1 (16.7) |
| Coagulopathy, n (%) | 49 (57.0) | 46 (57.5) | 3 (50.0) |
| AKI, n (%) | 35 (40.1) | 31 (38.8) | 4 (66.7) |
| Liver injury, n (%) | 34 (39.5) | 32 (40.0) | 2 (33.3) |
| Delirium, n (%) | 11 (12.8) | 11 (13.8) | 0 (0) |
| Intracerebral hemorrhage, n (%) | 1 (1.2) | 1 (1.3) | 0 (0) |
| Hypoxic-ischemic brain injury, n (%) | 2 (2.3) | 2 (2.5) | 0 (0) |
| Flaccid paralysis, n (%) | 5 (6.3) | 1 (1.3) | 4 (66.7) |
| Rhabdomyolysis | 2 (2.3) | 2 (2.5) | 0 (0) |
| Treatment | |||
| Antiviral therapy, n (%) | 67 (77.9) | 62 (77.5) | 5 (83.3) |
| Immunotherapy, n (%) | |||
| IVIg, n (%) | 70 (81.4) | 65 (81.3) | 5 (83.3) |
| Steroids, n (%) | 71 (82.6) | 67 (83.8) | 4 (66.7) |
| Anticoagulation, n (%)* | 48 (55.8) | 42 (52.5) | 6 (100) |
| Aspirin, n (%) | 10 (11.6) | 8 (10.0) | 2 (33.3) |
| Invasive MV, n (%) | 70 (81.4) | 64 (80.0) | 6 (100) |
| ECMO | 5 (5.8) | 5 (6.3) | 0 (0) |
| CRRT, n (%) | 16 (18.6) | 15 (18.8) | 1 (16.7) |
| Outcome | |||
| Death, n (%)* | 55 (64.0) | 54 (67.5) | 1 (16.7) |
| Follow-up duration, d, median (IQR) | 35.0 (20.6, 43.5) |
30.0 (20.0, 39.0) |
66.5 (54.8, 69.3) |
COVID-19, corona virus disease 2019; AIS, acute ischemic stroke; SD, standard deviation; PMH, past medical history; CAD, coronary artery disease; AF, atrial fibrillation; AKI, acute kidney injury; IVIg, intravenous immunoglobulin; MV, mechanical ventilation; ECMO, extracorporeal membrane oxygenation; CRRT, continuous renal replacement therapy; IQR, interquartile range.
*
P < 0.05.